Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Follow up of Autoantibodies in Active Tuberculosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: October 27, 2007
Last updated: October 29, 2007
Last verified: October 2007
We have previoulsy shown that patients with active Tuberculosis develop a wide array of autoantibodies including rheumatoid factor, anti-CCP, Antinuclear facyor and anti Sm antibodies. The purpose of this study is to evaluate whether the level of autoantibodies decrease after treatment aganist tuberculosis.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Follow up of Autoantibodies in Active Tuberculosis

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • Follow up after levels of autoantibodies [ Time Frame: 1 year ]

Biospecimen Retention:   Samples Without DNA
Serum of patients

Estimated Enrollment: 50
Study Start Date: November 2007
Estimated Study Completion Date: November 2008
Patients with tuberculosis
Healthy controls


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with active tuberculosis who are currently receiving anti tuberculosis drugs

Inclusion Criteria:

  • Active Tuberculosis treated

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00551226

Contact: Ori Elkayam, M.D 97236973668

Tel Aviv Medical Center Not yet recruiting
Tel Aviv, Israel, 64239
Contact: Ori Elkayam, M.D    97236973668   
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Principal Investigator: Ori Elkayam, M.D Tel Aviv Medical Center
  More Information Identifier: NCT00551226     History of Changes
Other Study ID Numbers: 314-07 
Study First Received: October 27, 2007
Last Updated: October 29, 2007
Health Authority: Israel: Ministry of Health

Keywords provided by Tel-Aviv Sourasky Medical Center:
Patients with tuberculosis

Additional relevant MeSH terms:
Latent Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Immunologic Factors
Physiological Effects of Drugs processed this record on October 21, 2016